Market-leading intellectual property is an indicator of superior business performance and investment returns
New York, New York (PRWEB) September 07, 2012
EndoSphere Inc. is pleased to announce that it has been selected to present at MDB Capital Group’s prestigious 3rd Annual Bright Lights Conference, which will take place September 9th - 11th at the New York Palace Hotel in New York City. EndoSphere will be presenting on Tuesday, September 11, 2012.
Bright Lights underscores MDB's commitment to advancing the financial markets' understanding of disruptive technologies and intellectual property as foundational sources of value creation. It is Wall Street’s only conference of its kind, focusing exclusively on companies MDB believes can transform their industries with game changing technology. EndoSphere was hand-selected by MDB as one of approximately 30 public and private companies to present at this exclusive, invitation-only event.
EndoSphere has built an intellectual property portfolio of 29 issued and pending U.S. and international patents. The company’s flagship product, the Satisphere™ System, is a noninvasive treatment for one of the world's largest health issues: obesity and its co-morbidities. The Satisphere device is an endoscopically-insertable device that improves the regulation of appetite and satiety by using the body’s natural physiology. Treatment using the Satisphere device is incisionless, reversible and repeatable. Clinical studies have shown that the Satisphere System enables obese patients to achieve significant weight loss without invasive surgery or medication. The device has received CE Mark regulatory approval for commercialization in 31 countries.
Worldwide obesity rates have become staggering. According to the Centers for Disease Control (CDC), obesity rates increased so dramatically during the past decade that today, more than 35 percent of U.S. adults suffer from obesity. By comparison, in 2000, not a single U.S. state had an obesity rate above 30 percent. Annual costs attributed to obesity and its co-morbidities have been estimated at $147 billion and rising.
"Market-leading intellectual property is an indicator of superior business performance and investment returns," commented Christopher Marlett, CEO at MDB Capital Group. "It’s a rare and exciting opportunity to have so many key players that are advancing some of today’s most innovative technologies together under one roof. We look forward to sharing the Satisphere System, EndoSphere’s breakthrough device for treating metabolic diseases including obesity and type 2 diabetes, with other innovators and investors at Bright Lights 2012.”
Bright Lights 2012 will host panels and presentations featuring industry-leading entrepreneurs, inventors and experts in intellectual property and the capital markets. To learn more about the event or to request an invitation, visit: http://mdb.com/2012-bright-lights-conference.html.
About EndoSphere Inc.
EndoSphere Inc. is a pioneer of endoscopically-insertable medical technologies. The company has developed a portfolio of 29 issued and pending U.S. and international patents. EndoSphere's flagship product, the Satisphere™ System, is a noninvasive treatment for metabolic diseases including obesity and type 2 diabetes. EndoSphere is a portfolio company of Broadline Capital, Ohio TechAngel Funds II and III, Co-Investment Fund, Glengary LLC, Physician Investment Group, North Coast Angel Fund II, QCA First Fund III, and EI Millstream Investment LLC. For more information, visit http://www.EndoSphereInc.com.
About MDB Capital Group
MDB Capital Group LLC is an investment banking and institutional research firm focused exclusively on companies possessing or seeking to develop market changing, disruptive technologies and intellectual property. For more information on MDB Capital Group, visit http://www.mdb.com.